drugset / Trial / NCT02778594
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa 100 mg/benserazide 25 mg (Madopar® HBS 125).
Timeline
- Start
- 2005-09
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIA 3-202 | Unknown | 50 mg | Oral |
| Subject | BIA 3-202 | Unknown | 100 mg | Oral |
| Subject | BIA 3-202 | Unknown | 200 mg | Oral |
| Subject | Levodopa | Unknown | 100 mg | Oral |
| Background | benserazide | Small molecule | 25 mg | Oral |